How today’s biotech leaders are navigating complexity
Conviction without adaptability becomes stubbornness. Transparency without conviction becomes noise. Perspective without action becomes philosophy. Together, these three capabilities create something increasingly essential for biotech leaders: the ability to move forward decisively in the face of profound uncertainty. Episodes 3-5 of Season 2 of Parexel Biotech's podcast, Clinical Trialblazers, explore how experienced leaders navigate this complexity.
Across these episodes, three leaders offered distinct perspectives on how those principles are applied in today’s biotech landscape. Heather Turner, CEO of LB Pharmaceuticals, reflected on her transition from lawyer to biotech CEO. Parexel co-founder, Joe von Rickenbach, shared lessons from more than three decades of CRO leadership, the entrepreneurial mindset that helped build the organization and his perspective on the future of clinical research. In the latest episode, Reenie McCarthy, CEO of Mighty Therapeutics, discussed the complex journey to securing FDA approval for the first approved therapy for Barth syndrome, including the scientific, regulatory and strategic challenges encountered along the way.
Conviction and adaptability must coexist
One of the strongest themes across all three conversations was the relationship between conviction and adaptability.
In biotech, leaders are often required to make consequential decisions before all the information needed to inform those decisions is available. In today's environment, those decisions are made against a backdrop of tighter funding, increasing development costs and continued pressure to demonstrate value earlier in the development process. Heather discussed the challenge of balancing risk and benefit while leading through uncertainty, recognizing that waiting for perfect information is rarely an option. Instead, leaders must determine when they have enough evidence to move forward and when additional information is worth the time and resources required to obtain it.
Reenie’s experience at Mighty Therapeutics offers a particularly powerful example. Following disappointing early trial results and regulatory hurdles, the company continued advancing the development of Elamipretide for Barth syndrome because leadership remained convinced by the totality of the evidence, including the experiences being reported by patients. As additional patient and investigator data emerged, Reenie reflected that the “conviction that we should keep going was improving on the strength of those data,” even though “our certainty in the outcome was not.” At the same time, conviction did not mean rigidity. Throughout the development process, the company adapted its regulatory strategy, development plans and approach in response to new information and changing circumstances.
Joe described a similar dynamic at an organizational level. Over three decades, clinical research evolved dramatically, and Parexel evolved alongside it. New technologies, new operating models and new approaches to development continually reshaped the industry. Looking ahead, he sees artificial intelligence as the next example of how organizations must remain adaptable — embracing new tools and ways of working while staying focused on the core objective of improving execution and patient outcomes.
These conversations suggest that leadership is not about holding a position indefinitely. It is about maintaining conviction in the objective while remaining adaptable in how it is achieved.
Transparency becomes a strategic asset
The need for transparency surfaced repeatedly in Clinical Trialblazers conversations as a critical enabler of progress, particularly in situations where uncertainty, complexity and competing stakeholder interests had to be navigated simultaneously. As development becomes more collaborative and stakeholders expect greater visibility into decision-making, transparency is increasingly becoming a strategic differentiator rather than simply a communications principle.
Reenie repeatedly returned to the importance of openness throughout the development of Elamipretide and treated transparency as an operational strategy. In situations with extended timelines, limited data and uncertain outcomes, transparency helped her build trust and collaboration while sustaining progress. Reenie’s team maintained ongoing dialogue with regulators, investigators and the patient community to build alignment, trust and shared understanding as decisions evolved. Internally, transparency around risks, setbacks and priorities helped maintain momentum through periods of uncertainty.
Heather highlighted a related principle through her approach to leadership. Whether navigating complex decisions or supporting future leaders within the industry, she emphasized the importance of communication, openness and fostering environments where people can contribute perspectives beyond their immediate area of expertise.
Joe’s perspective on the future of clinical research reinforces the same trend. Looking ahead, he noted that “the onset of AI is going to enable a level of transparency and execution that we would've never even dreamed of 25 years ago.”
As data, technology and AI continue to reshape the industry, greater transparency may create new opportunities for collaboration, more informed decision-making and improved patient experiences. The broader lesson across these conversations is that trust is rarely built after success arrives but often established during periods of uncertainty, long before outcomes are known.
Expanding perspective becomes a leadership requirement
As responsibilities grow, leadership often requires a broader perspective than the one that initially brought someone into the role. As organizations become more specialized and development programs increasingly span multiple partners, disciplines and technologies, leaders are expected to integrate perspectives well beyond their own expertise.
For Heather, that evolution involved moving from legal to enterprise leadership, a transition that fundamentally changed how she approached decision-making. She explained, “As a lawyer, your job is to identify and mitigate risk. What I've realized is that as an executive or as a CEO, when you think about this risk-benefit calculus, I really need to lead with benefit.”
Reenie experienced a similar transition when moving from investor and board member to CEO. What began as an interim leadership role quickly became an immersion into scientific, regulatory, operational and organizational challenges that extended far beyond board-level oversight. She described the experience as a steep learning curve that required understanding every aspect of drug development in greater depth.
Joe reflected on this evolution over more than three decades of leadership. Building Parexel required adapting not only to industry changes but also to the changing demands of leadership as the organization grew from a startup into a global enterprise.
Across these leaders’ experiences, effective leadership requires seeing beyond the boundaries of any single function or area of expertise. As responsibility grows, success depends on the ability to integrate expertise across many functions.
Key takeaways for biotech leaders
What becomes clear across these episodes is that conviction, transparency and expanded perspective are not competing priorities, but mutually reinforcing capabilities. Conviction without adaptability can limit progress, transparency without perspective can become reactive and perspective without conviction can make it difficult to move forward when certainty is out of reach. The leaders demonstrate that cultivating all three simultaneously is becoming an increasingly important differentiator as biotech organizations navigate scientific complexity, regulatory scrutiny and emerging technologies.
As Season 2 of Clinical Trialblazers continues, we look forward to additional perspectives on how leaders are navigating these challenges and opportunities across biotech and clinical research.
Hear the full conversations with Heather, Joe and Reenie on Clinical Trialblazers here.
Related Insights